AKR1C3 Recombinant Antibody

$25 ug total protein per lane of various lysates (see on figure) probed with AKR1C3 monoclonal antibody, unconjugated (bsm-62035R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.$

25 ug total protein per lane of various lysates (see on figure) probed with AKR1C3 monoclonal antibody, unconjugated (bsm-62035R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.

Applications

WB
FCM
IF(ICC)
IP

Reactivity

Human
Mouse
Rat

Overview
Catalog #	bsm-62035r-100ul
Product Name	AKR1C3 Recombinant Antibody
Applications	WB, FCM, IF(ICC), IP
Reactivity	Human, Mouse, Rat
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human AKR1C3
Clonality	Recombinant
Isotype	IgG
Concentration	Lot dependent
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol
Storage Condition	Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	8644
Swiss Prot	P42330
Subcellular location	Cytoplasm
Synonyms	DD3; DDX; HA1753; HAKRB; HAKRe; HSD17B5; KIAA0119; hluPGFS.
Background	Cytosolic aldo-keto reductase that catalyzes the NADH and NADPH-dependent reduction of ketosteroids to hydroxysteroids. Acts as a NAD(P)(H)-dependent 3-, 17- and 20-ketosteroid reductase on the steroid nucleus and side chain and regulates the metabolism of androgens, estrogens and progesterone.
Application Dilution
WB	1:500-2000
FCM	FCM1:50-100
IF(ICC)	IFICC1:50-200
IP	IP1:20-50